Teva Pharmaceutical Industries Limited Sponsored ADR Stock

$16.40

0.79% day before yesterday

NYSE, Jul 11, 10:10 pm CET

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Teva Pharmaceutical Industries Limited Sponsored ADR Stock price

$16.40

+4.83 41.75% 5Y

NYSE, Closing price Fri, Jul 11 2025

-0.13 0.79%

ISIN

US8816242098

Symbol

TEVA

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$19.2b

Enterprise Value

$34.1b

Net debt

$15.0b

Cash

$1.7b

Shares outstanding

1.1b

Valuation (TTM | estimate)

P/E

negative | 6.3

P/S

1.2 | 1.1

EV/Sales

2.1 | 2.0

EV/FCF

44.5

P/B

3.1

Dividends

DPS

$0.00

Yield 1Y | 5Y

0.0% | 0.0%

Growth 1Y | 5Y

- | -

Payout 1Y | 3Y

0.0% | 0.0%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$16.6b | $17.5b

EBITDA

$4.7b | $5.0b

EBIT

$3.7b | $4.3b

Net Income

$-1.3b | $3.0b

Free Cash Flow

$766.0m

Growth (TTM | estimate)

Revenue

3.8% | 5.7%

EBITDA

-0.9% | 7.3%

EBIT

1.3% | 20.2%

Net Income

-160.9% | 280.2%

Free Cash Flow

-12.7%

Financial Health

Equity Ratio

13.7%

Return on Equity

-30.5%

ROCE

13.5%

ROIC

31.7%

Debt/Equity

2.7

EPS

$-1.1

FCF per Share

$0.7

Short interest

3.5%

Employees

Rev per Employee

As a Free StocksGuide user, you can view scores for all 7,006 stocks worldwide.

Get Started for Free Today

Teva Pharmaceutical Industries Limited Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

3x Hold

33%

6x Sell

67%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Teva Pharmaceutical Industries Limited Sponsored ADR forecast:

Hold

33%

Sell

67%

Analyst Estimates with Stock Price Targets

Financial data from Teva Pharmaceutical Industries Limited Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	16,616 16,616	4% 4% 100%
- Direct Costs	8,227 8,227	4% 4% 50%
Gross Profit	8,389 8,389	4% 4% 50%
- Selling and Administrative Expenses	3,734 3,734	5% 5% 22%
- Research and Development Expense	1,003 1,003	4% 4% 6%
EBITDA	4,718 4,718	1% 1% 28%
- Depreciation and Amortization	1,031 1,031	8% 8% 6%
EBIT (Operating Income) EBIT	3,687 3,687	1% 1% 22%
Net Profit	-1,286 -1,286	161% 161% -8%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teva Pharmaceutical Industries Limited Sponsored ADR Stock News

Neutral

24/7 Wall Street

●

11 days ago

Billionaire Stanley Druckenmiller Sold Palantir And Buying This Stock Instead

Billionaire investment legend Stanley Druckenmiller is quickly becoming one of my favorite big-money managers to follow quarter to quarter.

Neutral

GlobeNewsWire

●

16 days ago

Teva Releases Q2 2025 Aide Memoire

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website.

Neutral

GlobeNewsWire

●

17 days ago

Teva to Host Conference Call to Discuss Second Quarter 2025 Financial Results at 8 a.m. ET on July 30, 2025

TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.

More Teva Pharmaceutical Industries Limited Sponsored ADR News

Company Profile

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The company was founded in 1901 and is headquartered in Petah Tikva, Israel.

Head office	Israel
CEO	Richard Francis
Founded	1901
Website	www.tevapharm.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now